iTolerance, Inc., a Company Pioneering Regenerative Medicine Without Immunosuppression, Announces Leadership Team
Lead product candidate, ITOL-101, for the treatment of Type 1 Diabetes entering IND-enabling studies
Anthony Japour, M.D., a seasonedbiotech and pharmaceutical executive with over 30 years of experience, appointed as Chief Executive Officer
Camillo Ricordi, M.D., one of the world s leading scientists in diabetes cure-focused research, cell transplantation and regenerative medicine, appointed as Chief Scientist
SAN MATEO, CA / ACCESSWIRE / June 9, 2021 / iTolerance, Inc
. ( iTolerance or the Company ), a biotechnology company focused on the development of innovative regenerative medicines, today announced the formation of its Executive Leadership Team with the hiring of Anthony Japour, M.D. as Chief Executive Officer and Camillo Ricordi, M.D. as Chief Scientist.
Forward-Looking Statements
This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to var